Pharma & Biotech Events & Conferences
Refine Search
Pharmaceutical
US pharma giant Pfizer will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. 14 May 2025
Pharmaceutical
Denmark’s Novo Nordisk has presented data at the European Congress of Obesity (ECO) showing that Wegovy (semaglutide injection) 2.4 mg reduced the risk of major adverse cardiovascular events (MACE) by 37% in adults with overweight and obesity and cardiovascular (CV) disease, compared to placebo, on top of standard of care, within the first three months of treatment. 13 May 2025
Biotechnology
US pharma firm BioMarin Pharmaceutical saw its shares rise nearly 4% to $61.09 this morning, after it released positive new data for its Voxzogo (vosoritide). 12 May 2025
Pharmaceutical
Novo Nordisk today presented data from the Phase III REAL8 basket, which showed that once-weekly Sogroya (somapacitan) was non-inferior to its own once-daily growth hormone Norditropin (somatropin). 12 May 2025
Pharmaceutical
UK pharma major GSK has unveiled full Phase III data showing its experimental drug linerixibat significantly reduced itching in people with primary biliary cholangitis (PBC), a rare autoimmune liver disorder. The results were presented at this year’s European Association for the Study of the Liver (EASL) meeting. 9 May 2025
Pharmaceutical
French drugmaker Ipsen today announced new data from two late-breaking presentations on Iqirvo (elafibranor) during the European Association for the Study of the Liver congress. 7 May 2025
Pharmaceutical
US healthcare giant Johnson & Johnson has shared new findings for TAR-200, an intravesical gemcitabine releasing system, for patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC). 28 April 2025
Biotechnology
US pharma major Pfizer reported new Phase III data over the weekend showing that its investigational PD-1 inhibitor sasanlimab, delivered subcutaneously, significantly improved outcomes for certain patients with non-muscle invasive bladder cancer (NMIBC) when used alongside Bacillus Calmette-Guérin (BCG) therapy. 28 April 2025
Biotechnology
UCB, Belgium’s largest pharma company, has announced findings from a collection of real-world evidence studies to reaffirm the effectiveness and clinical impact of romosozumab, the only dual-acting osteoporosis treatment that increases bone formation and decreases bone resorption, around the world. 14 April 2025
Pharmaceutical
At the recent American Academy of Neurology (AAN) 2025 annual meeting, Axsome Therapeutics presented promising data for AXS-05 (bupropion + dextromethorphan) in treating agitation associated with Alzheimer’s disease (AD). 10 April 2025
Pharmaceutical
Positive results from the PURSUIT Phase IIb trial of AstraZeneca’s AZD0780 have shown a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of standard-of-care statin therapy, as compared with placebo. 1 April 2025
Pharmaceutical
Merck & Co -as announced the first presentation of full results from the Phase III ZENITH trial of Winrevair (sotatercept-csrk) compared to placebo in adults with pulmonary arterial hypertension World Health Organization functional class (FC) III or IV at high risk of mortality who were on maximum tolerated background PAH therapy. 1 April 2025
Pharmaceutical
Eli Lilly is advancing its ambitions in cardiometabolic medicine with new mid-stage data showing that solbinsiran, an RNA interference therapy targeting ANGPTL3, can meaningfully reduce key lipid markers in patients with mixed dyslipidemia. 1 April 2025
Biotechnology
Cambridge, USA-based Anthos Therapeutics presented two new analyses from its landmark AZALEA-TIMI 71 study at the American College of Cardiology Annual Scientific Session (ACC.25) demonstrating the novel Factor XI inhibitor abelacimab significantly reduced bleeding in patients regardless of age or bleeding risk. 31 March 2025
Biotechnology
Brii Biosciences has reported promising interim results from its Phase II ENSURE study of elebsiran, a hepatitis B therapeutic, in combination with pegylated interferon, reinforcing its strategy to identify patients more likely to benefit from curative therapies. 31 March 2025
Pharmaceutical
Novo Nordisk has reported new Phase IIIb data showing its GLP-1 drug semaglutide, in both oral and injectable forms, led to significant health benefits in adults with type 2 diabetes facing cardiovascular complications. 31 March 2025
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences today presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with once-daily Ingrezza (valbenazine) capsules. 20 March 2025
Pharmaceutical
US pharma giant Merck & Co has presented positive results from two pivotal Phase III trials of the investigational, once-daily, oral, two-drug regimen of doravirine/islatravir [DOR/ISL (100mg/0.25mg)] in adults with HIV-1 infection that is virologically suppressed on bictegravir/emtricitabine/tenofovir alafenamide [BIC/FTC/TAF (50mg/200mg/25mg)] in trial MK-8591A-052 ) or antiretroviral therapy [baseline antiretroviral therapy (bART)] in trial MK-8591A-051. 13 March 2025
Pharmaceutical
Specialist HIV company ViiV Healthcare, which is majority owned by UK pharma major GSK, today announced positive findings from the company’s EMBRACE Phase IIb study. 12 March 2025
Biotechnology
US biotech Amgen and Japanese partner Kyowa Kirin announced new results from the ongoing ROCKET Phase III clinical trial program evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in moderate to severe atopic dermatitis (AD). 10 March 2025
Pharmaceutical
US pharma giant Pfizer will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. 14 May 2025
Pharmaceutical
Denmark’s Novo Nordisk has presented data at the European Congress of Obesity (ECO) showing that Wegovy (semaglutide injection) 2.4 mg reduced the risk of major adverse cardiovascular events (MACE) by 37% in adults with overweight and obesity and cardiovascular (CV) disease, compared to placebo, on top of standard of care, within the first three months of treatment. 13 May 2025
Biotechnology
US pharma firm BioMarin Pharmaceutical saw its shares rise nearly 4% to $61.09 this morning, after it released positive new data for its Voxzogo (vosoritide). 12 May 2025
Pharmaceutical
Novo Nordisk today presented data from the Phase III REAL8 basket, which showed that once-weekly Sogroya (somapacitan) was non-inferior to its own once-daily growth hormone Norditropin (somatropin). 12 May 2025
Pharmaceutical
UK pharma major GSK has unveiled full Phase III data showing its experimental drug linerixibat significantly reduced itching in people with primary biliary cholangitis (PBC), a rare autoimmune liver disorder. The results were presented at this year’s European Association for the Study of the Liver (EASL) meeting. 9 May 2025
Pharmaceutical
French drugmaker Ipsen today announced new data from two late-breaking presentations on Iqirvo (elafibranor) during the European Association for the Study of the Liver congress. 7 May 2025
Pharmaceutical
US healthcare giant Johnson & Johnson has shared new findings for TAR-200, an intravesical gemcitabine releasing system, for patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC). 28 April 2025
Biotechnology
US pharma major Pfizer reported new Phase III data over the weekend showing that its investigational PD-1 inhibitor sasanlimab, delivered subcutaneously, significantly improved outcomes for certain patients with non-muscle invasive bladder cancer (NMIBC) when used alongside Bacillus Calmette-Guérin (BCG) therapy. 28 April 2025
Biotechnology
UCB, Belgium’s largest pharma company, has announced findings from a collection of real-world evidence studies to reaffirm the effectiveness and clinical impact of romosozumab, the only dual-acting osteoporosis treatment that increases bone formation and decreases bone resorption, around the world. 14 April 2025
Pharmaceutical
At the recent American Academy of Neurology (AAN) 2025 annual meeting, Axsome Therapeutics presented promising data for AXS-05 (bupropion + dextromethorphan) in treating agitation associated with Alzheimer’s disease (AD). 10 April 2025
Pharmaceutical
Positive results from the PURSUIT Phase IIb trial of AstraZeneca’s AZD0780 have shown a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of standard-of-care statin therapy, as compared with placebo. 1 April 2025
Pharmaceutical
Merck & Co -as announced the first presentation of full results from the Phase III ZENITH trial of Winrevair (sotatercept-csrk) compared to placebo in adults with pulmonary arterial hypertension World Health Organization functional class (FC) III or IV at high risk of mortality who were on maximum tolerated background PAH therapy. 1 April 2025
Pharmaceutical
Eli Lilly is advancing its ambitions in cardiometabolic medicine with new mid-stage data showing that solbinsiran, an RNA interference therapy targeting ANGPTL3, can meaningfully reduce key lipid markers in patients with mixed dyslipidemia. 1 April 2025
Biotechnology
Cambridge, USA-based Anthos Therapeutics presented two new analyses from its landmark AZALEA-TIMI 71 study at the American College of Cardiology Annual Scientific Session (ACC.25) demonstrating the novel Factor XI inhibitor abelacimab significantly reduced bleeding in patients regardless of age or bleeding risk. 31 March 2025
Biotechnology
Brii Biosciences has reported promising interim results from its Phase II ENSURE study of elebsiran, a hepatitis B therapeutic, in combination with pegylated interferon, reinforcing its strategy to identify patients more likely to benefit from curative therapies. 31 March 2025
Pharmaceutical
Novo Nordisk has reported new Phase IIIb data showing its GLP-1 drug semaglutide, in both oral and injectable forms, led to significant health benefits in adults with type 2 diabetes facing cardiovascular complications. 31 March 2025
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences today presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with once-daily Ingrezza (valbenazine) capsules. 20 March 2025
Pharmaceutical
US pharma giant Merck & Co has presented positive results from two pivotal Phase III trials of the investigational, once-daily, oral, two-drug regimen of doravirine/islatravir [DOR/ISL (100mg/0.25mg)] in adults with HIV-1 infection that is virologically suppressed on bictegravir/emtricitabine/tenofovir alafenamide [BIC/FTC/TAF (50mg/200mg/25mg)] in trial MK-8591A-052 ) or antiretroviral therapy [baseline antiretroviral therapy (bART)] in trial MK-8591A-051. 13 March 2025
Pharmaceutical
Specialist HIV company ViiV Healthcare, which is majority owned by UK pharma major GSK, today announced positive findings from the company’s EMBRACE Phase IIb study. 12 March 2025
Biotechnology
US biotech Amgen and Japanese partner Kyowa Kirin announced new results from the ongoing ROCKET Phase III clinical trial program evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in moderate to severe atopic dermatitis (AD). 10 March 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Cidara is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives. The firm is applying its proprietary Cloudbreak platform to develop antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze